Get the Stockscreener App
102.47
0.03%
-0.04
Exact Sciences Corp stock is traded at $102.47, with a volume of 1.35M.
It is down -0.03% in the last 24 hours and up +0.89% over the past month.
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
See More
Previous Close:
$102.51
Open:
$102.55
24h Volume:
1.35M
Relative Volume:
0.26
Market Cap:
$19.46B
Revenue:
$2.83B
Net Income/Loss:
$-1.02B
P/E Ratio:
-18.60
EPS:
-5.51
Net Cash Flow:
$194.14M
1W Performance:
+0.12%
1M Performance:
+0.89%
6M Performance:
+111.33%
1Y Performance:
+84.04%
1-Day Range:
$102.40
$102.59
1-Week Range:
$102.14
$102.66
52-Week Range:
$38.81
$102.66
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
102.47 | 19.47B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
623.72 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.34 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
700.90 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
242.12 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
136.31 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Mizuho | Outperform → Neutral |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement - Insider Monkey
EFG Asset Management North America Corp. Purchases 12,900 Shares of Exact Sciences Corporation $EXAS - MarketBeat
3 Reasons to Buy This Dividend King After Its Steep Sell-Off - The Motley Fool
A Look At Exact Sciences (EXAS) Valuation After Its Strong Recent Share Price Momentum - Yahoo! Finance Canada
Lobbying Update: $420,000 of EXACT SCIENCES lobbying was just disclosed - Quiver Quantitative
Halper Sadeh Investigates Potential Securities Violations by Penumbra, Exact Sciences, DigitalBridge, and Flushing Financial - Intellectia AI
Mizuho downgrades Exact Sciences (EXAS) - MSN
Short Squeeze: Is Village Farms International Inc stock a good pick for beginnersJuly 2025 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Assessing Exact Sciences: Insights From 16 Financial Analysts - Benzinga
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Playbook on Early Cancer Detecti - AD HOC NEWS
Exact Sciences (EXAS) Downgraded by Mizuho, Price Target Raised to $105 | EXAS Stock News - GuruFocus
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Chevron, Domino’s Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More - AOL.com
Exact Sciences (EXAS) Rose Following the Acquisition Announcement by Abbott - Yahoo Finance
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Chevron, Domino's Pizza, Doximity, Exact Sciences, Intel, NetApp, StubHub, Toast, and More - 24/7 Wall St.
Mizuho downgrades Exact Sciences stock to Neutral on Abbott acquisition By Investing.com - Investing.com Nigeria
Mizuho downgrades Exact Sciences stock to Neutral on Abbott acquisition - Investing.com
Exact Sciences’ MCED Test Study: A Potential Game-Changer in Early Cancer Detection - MSN
Exact Sciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences CorporationEXAS - marketscreener.com
Why Abbott Laboratories (ABT) Story Is Shifting With Exact Sciences Deal Talk And Legal Wins - Yahoo Finance
Robeco Institutional Asset Management B.V. Lowers Stake in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation (EXAS) Stock Analysis: Strong Revenue Growth Amid High Valuation - DirectorsTalk Interviews
Exact Sciences (EXAS) Valuation Check After Strong Multi Month Share Price Momentum - Yahoo Finance
Is Exact Sciences (EXAS) Still Attractive After An 81% One Year Share Price Surge - Yahoo Finance
Is Exact Sciences Corporation stock a safe haven assetInsider Selling & Real-Time Volume Trigger Notifications - ulpravda.ru
Peregrine Capital Management LLC Grows Position in Exact Sciences Corporation $EXAS - MarketBeat
Will Exact Sciences Corporation stock benefit from sector rotationGold Moves & Low Drawdown Investment Strategies - ulpravda.ru
How Exact Sciences Corporation stock reacts to job market dataMarket Trend Report & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
How Exact Sciences Corporation stock reacts to bond yieldsJuly 2025 Rallies & Risk Controlled Daily Plans - ulpravda.ru
Can Exact Sciences Corporation (EXK) stock retain market dominanceJuly 2025 Trends & Safe Capital Growth Trade Ideas - ulpravda.ru
Abbott’s $105 Bid Put Exact Sciences Back In Play - Finimize
Assessing Exact Sciences (EXAS) Valuation After A Strong Momentum-Driven Share Price Run - simplywall.st
EXAS Stock Rating Downgraded to 'In-Line' by Evercore ISI Group - GuruFocus
Exact Sciences Corporation (EXAS) Stock Analysis: Unveiling Growth Potential In Cancer Diagnostics - DirectorsTalk Interviews
Abbott bets on cancer screening with $23 billion Exact Sciences deal - MSN
Pharma News: Can Exact Sciences Corporation EXK stock retain market dominanceVolume Spike & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
1 High-Flying Stock on Our Watchlist and 2 We Question - Finviz
Top 2 Health Care Stocks That May Crash In Q1 - Benzinga
Cwm LLC Purchases 28,975 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Stock Is Going Wild: Is This Cancer-Test Giant a Hidden Gem or Total Trap? - AD HOC NEWS
19,260 Shares in Exact Sciences Corporation $EXAS Purchased by Strait & Sound Wealth Management LLC - MarketBeat
Exact Sciences Corp.: Turning DNA Into a Weapon Against Cancer - AD HOC NEWS
Smart Oncology: 5 Stocks Chasing the $317B Prize - The Globe and Mail
Alert from law firm on Exact Sciences-Abbott deal withdrawn - marketscreener.com
Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie ... - Bluefield Daily Telegraph
Should You Continue to Hold EXAS Stock in Your Portfolio Now? - WV News
Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Cancer Playbook - AD HOC NEWS
Exact Sciences Corp. Stock Tests Investor Patience as Diagnostics Story Enters a New Act - AD HOC NEWS
Exact Sciences accelerates executive bonuses and equity awards ahead of merger By Investing.com - Investing.com Australia
Exact Sciences accelerates executive bonuses and equity awards ahead of merger - Investing.com Nigeria
Harbor Capital Advisors Inc. Sells 29,990 Shares of Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation (NASDAQ:EXAS) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.70%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):